| Literature DB >> 30693274 |
.
Abstract
[This corrects the article DOI: 10.3389/fcimb.2018.00419.].Entities:
Keywords: Plasmodium; apoptosis; eryptosis; host-directed therapy; host-pathogen interaction; malaria; programmed cell death
Year: 2019 PMID: 30693274 PMCID: PMC6340367 DOI: 10.3389/fcimb.2018.00455
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Effect of eryptosis inducers on P. berghei in vivo development.
| Eryptosis inducers | Amiodarone | ns | 64% | 70% | N/A | Bobbala et al., | |
| Anandamide | ns | 67% | 70% | N/A | Bobbala et al., | ||
| Aurothiomalate | ns | 44% | 55% | Alesutan et al., | |||
| Dimethylfumarate | ns | 83% | 60% | ns | Ghashghaeinia et al., | ||
| Amphotericin B | ns | ns | 50% | N/A | Siraskar et al., | ||
Eryptosis compounds were administered to P. berghei-infected mice 8 days post-parasite infection. Eryptosis features of infected red blood cells (iRBC) and bystander uninfected red blood cells (uRBC), as well as parasitemia levels, mice survival outcome, and anemia levels effects were measured every day. For clarity purposes, the eryptosis phenotype observed is based only on reported PS exposure measurements. “Parasitemia decrease” indicates the decreased percentage in parasitemia of treated mice when compared to the untreated control (value calculated based on data provided in the original publication) when the difference reached significance. “Mice survival” indicates the percentage of viable treated mice when untreated controls reached 100% lethality rate. Compounds previously described as eryptotic inducers (see Table 1) that did not induce a significant increase in eryptosis of uRBC in these studies are indicated by .